Arcadia Biosciences (NASDAQ:RKDA) reported quarterly losses of $(1.78) per share which beat the analyst consensus estimate of $(2.52) by 29.37 percent. This is a 83.61 percent increase over losses of $(10.86) per share from the same period last year. The company reported quarterly sales of $1.255 million which beat the analyst consensus estimate of $1.194 million by 5.15 percent. This is a 1.87 percent increase over sales of $1.232 million the same period last year.
Arcadia Biosciences Q1 2024 GAAP EPS $(1.78) Beats $(2.52) Estimate, Sales $1.255M Beat $1.194M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.